CannabisNewsWire
Editorial Coverage: The opioid crisis in North America has
drawn attention to the urgent need for alternative medicines, and
hemp CBD products offer a viable plant-based option.
- An active ingredient in industrial hemp, Cannabidiol (CBD) can
be extracted to be used in a number of different products such as
topicals, tinctures, and capsules.
- The World Health Organization (WHO) has found CBD to be
nonpsychoactive, nonaddictive, and to have a positive effect on
patients’ health.
- Scientific studies have shown CBD to be effective in pain
relief and, therefore, it may be a healthier alternative to
addictive opioids.
Marijuana Company of America Inc. (OTC: MCOA) (MCOA
Profile) is actively engaged in producing all-natural
products containing CBD, including a recently released pain cream
that can be applied topically to relieve discomfort. Cronos
Group, Inc. (NASDAQ: CRON) has recently received a boost
in funds and a license to produce cannabis products in Australia,
allowing the company to grow its operations. Canopy Growth
Corporation (NYSE: CGC), which produces oils containing
CBD, is expanding into Lesotho and Colombia, exploring a global
pain-relief market. Aurora Cannabis, Inc. (OTCQX:
ACBFF), which already produces a wide range of medical
marijuana strains, is in the process of acquiring an R&D
company to strengthen its offerings. And Organigram
Holdings, Inc. (OTCQB: OGRMF) produces medical strains
that include a CBD option for patients and care providers eager to
benefit from this ingredient.
The Opioid Epidemic
The United States is facing one of its greatest medical crises
in decades — the opioid epidemic. During 2016
alone, 42,249 people died of opioid overdoses, 115 deaths every
day. Despite the attention being turned onto this problem, most states are seeing further increases rather than
declines in opioid abuse and its consequences. As the problem
grows, physicians, emergency rooms and other healthcare providers
are feeling pressure to find effective treatments for pain
management, one of the largest causes of the growing problem.
Though illegal drugs such as heroin play their part, this crisis
is fuelled by prescription drugs. The prescription painkiller
problem began in the 1990s, when pharmaceutical
companies persuaded healthcare providers that they could
prescribe opioid painkillers without risk of addiction. This proved
to be untrue, as large numbers of patients began misusing the
drugs. Today, an estimated 21–29 percent of
patients prescribed opioids misuse them, with 8–12 percent
developing a disorder. And while misuse of legal drugs is a huge
problem in its own right, it is also the gateway to illegal
opioids. However, by the time the problem was recognized, the
medical sector had become reliant on opioids. Pain relief is a
critical part of modern medicine, which helps patients manage
chronic conditions as well as cope with recovery from shorter-term
illnesses, accidents and operations. Simply abandoning opioids was
not an option.
An Alternative to Opioids
One option gaining increased attention may be the use of
all-natural cannabidiol (CBD) products, as a plant-derived option
to the use of synthetic prescription painkillers. These products do
not contain THC, the ingredient that gets cannabis users high, and
so can be used to provide relief without impairing a user’s normal
mental activities. Products containing CBD, which have recently
been developed by companies such as Marijuana Company of
America (MCOA
Profile), may offer a viable alternative to synthetic
medicines.
CBD applications and uses have benefitted from changes
surrounding that industry. Licenses to grow industrial hemp have
allowed companies to combine agriculture, R&D and product
development with those seeking medical uses for hemp. MCOA’s recently
established cultivation in Oregon is a prime example of this
work, with researchers developing better growing techniques and
improved plant strains that will allow them to extract higher
yields of CBD oil.
A Healthier Option?
Scientific research into the effectiveness of
CBD supports its potential in pain relief. A review of recent
studies found that it was generally effective in helping patients
manage their pain. Not only can it provide a viable alternative to
opioid painkillers.
The advantage of CBD over opioids appear to be that it may
provide a safer, healthier treatment option. CBD appears to be far
less physically and mentally addictive than many prescribed pain
medications. Patients can use it without experiencing the high
risks of addiction that accompany many prescription
painkillers.
The World Health Organization released a scientific research report conducted on CBD, which
found the compound to be nonpsychoactive and nonaddictive; the
report also noted that it has multiple health benefits. CBD oils
provide patients with access to the relief that medical marijuana
would bring but without many of the side effects.
Applied Medicine
By providing alternatives for relief, companies working with CBD
are providing a pathway out of the opioid epidemic. One example of
a CBD pain-management product is MCOA’s recently released hempSMART Pain Cream.
HempSMART Pain Cream is a topical treatment developed to reduce
discomfort, support joint mobility, and relax muscles. Each bottle
contains 300mg of full-spectrum CBD derived from industrial hemp,
combined with other natural plant-based extracts. The cream
contains the company’s own formulation of Ayurvedic herbs along
with menthol, cayenne pepper extract, rosemary oil, aloe gel, white
willow bark, arnica, wintergreen extract and tea tree oil.
Together, these ingredients appear to provide an immediate cooling
and soothing sensation, while the CBD helps to ease discomfort.
“We will continue to expand our health and wellness lines in
2018 to include more products,” said MCOA CEO Donald Steinberg.
“Pain Cream has been enthusiastically received by our affiliates
and customers.”
Pain Cream is just one of many hempSMART products already
developed by MCOA. As more is learned about the potential uses of
CBD in wellness products, the company will likely develop new
products and treatments. From hempSMART Brain, a brain-enhancing formulation, to hempSMART Face, a
CBD-infused cosmetic, the company is finding
new ways to deliver the benefits of this chemical compound.
Cannabis Companies Explore Potential of CBD
Meanwhile, patients looking for pain relief have the chance to
move away from prescription drugs and into treatments without the
same risks of addiction. A number of other companies are also
exploring the potential of CBD treatments.
One of the most prominent is Cronos Group, Inc. (NASDAQ:
CRON), the first Nasdaq-traded company purely focused on
cannabis. Though based in North America, the company has recently
started branching out, obtaining a
manufacturing license to produce products based on medical cannabis
in Australia. Boosted by funds raised through a recent public
offering, the company is set to become a global player in the field
of cannabis-derived treatments, including pain medication.
Canopy Growth Corporation (NYSE: CGC) is also
looking to bring cannabis and CBD treatments to a wider market.
Having previously acquired a cannabis company in Lesotho, giving it
access to the African market, the company is now expanding into
Latin America through the acquisition of a
Colombian company. Canopy Growth produces oils with varying
levels of CBD to meet the varying needs of customers.
One of the world’s largest cannabis companies, Aurora
Cannabis, Inc. (OTCQX: ACBFF) is heavily involved in pain
relief through its wide selection of medical cannabis strains. The
company recently took a step toward improving its research into
cannabis-derived medicine, thanks to the Canadian Competition
Bureau’s approval of a
proposed takeover of MedReleaf. By acquiring another
R&D-driven cannabis company, Aurora hopes to expand its own
research into CBD-based medicines.
Medical cannabis company Organigram Holdings, Inc.
(OTCQB: OGRMF) has produced a range of different strains,
including CBD-rich options. It has recently been licensed to expand its production facilities, allowing
the company to better meet the needs of a growing market.
With companies developing hemp-derived, CBD-based wellness
products, a new alternative to synthetic opioid-based medications
is emerging. CBD-based options may also provide access to the
benefits of medical cannabis without that product’s mind-altering
properties and other worrisome side effects.
For more information on Marijuana Company of America, visit
Marijuana
Company of America, Inc. (OTC: MCOA)
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize
corporate news and information, (3) enhanced press release
services, (4) social media distribution and optimization services,
and (5) a full array of corporate communication solutions. As a
multifaceted financial news and content distribution company with
an extensive team of contributing journalists and writers, CNW is
uniquely positioned to best serve private and public companies that
desire to reach a wide audience of investors, consumers,
journalists and the general public. CNW has an ever-growing
distribution network of more than 5,000 key syndication outlets
across the country. By cutting through the overload of information
in today’s market, CNW brings its clients unparalleled visibility,
recognition and brand awareness. CNW is where news, content and
information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and
or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by CNW are
solely those of CNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW for any investment
decisions by their readers or subscribers. CNW is a news
dissemination and financial marketing solutions provider and is NOT
registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW undertakes no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Cronos (NASDAQ:CRON)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cronos (NASDAQ:CRON)
Historical Stock Chart
From Sep 2023 to Sep 2024